All In Biotech

Drug Trial Radar · NCT02546583

Diagnosing and Targeting Mechanisms of Diuretic Resistance in Heart Failure

Last checked: Nov 20, 2026Latest source record: Aug 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 458 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

458

Actual

Start

Aug 31, 2015

Primary completion

Jan 23, 2020

Study completion Jan 23, 2020

Sponsor

Lead sponsor
Yale UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
First posted
Sep 11, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Diagnostic
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Effective diuresis is the primary goal of most acute decompensated heart failure hospitalizations, but diuretic resistance is common and our ability to detect it is limited. Further, there are therapeutically distinct groups of diuretic-resistant patients. These are not easily distinguished using currently available methods, leading to trial-and-error based treatment that promotes lengthy hospitalizations. The aims of this study are: 1. To develop inexpensive and efficient tools to predict diuretic response 2. To understand the prevalence of therapeutically targetable mechanisms of diuretic resistance using endogenous lithium clearance 3. To develop methodology to differentiate diuretic resistance mechanisms using common/inexpensive laboratory tests 4. To provide proof of concept that mechanistically tailored diuretic therapy can improve natriuresis

Conditions

  • Heart Failure

Interventions

  • Increased Intravenous Bolus Loop Diuretic Dose (Bumetanide or Furosemide)Drug

    An increase to 2.5x the Visit 1 dose of loop diuretic (bumetanide or furosemide).

  • IV ChlorothiazideDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Accuracy of sodium prediction equation in predicting suboptimal natriuretic response to a dose of diureticsTime frame: 6 hours
  2. Prevalence of mechanistic sub types of Diuretic Resistance (DR) as defined by cutoff values of change in fractional excretion of lithiumTime frame: 6 hours
  3. Accuracy of prediction of mechanistic sub types of DR using universally available laboratory testsTime frame: 6 hours
  4. Change in total 6-hour sodium output between observational and randomized intervention study days, compared between intervention groupsTime frame: 6 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Yale University

    New Haven, Connecticut

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.